Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

About this update from Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL. The first presentation characterizes the overall burden of post-bariatric hypoglycemia (PBH) in the U.S. on healthcare resource utilization, economic impact, and quality of life. The second presentation describes participant-centric trial design considerations for the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of PBH. The ENDO 2026 presentation details are as follows: Abstract Title: Characterizing the Burden of Post-Bariatric Hypoglycemia in the United States Presenter: Colleen Craig, MD Poster Number: SUN-570 Session Title: Diabetes and Vascular Disease: Hypoglycemia II Date and Time: Sunday, June 14, 2026, 12:00 p.m. – 1:30 p.m. CT Abstract Title: Participant-Informed Design Considerations in Phase 3 LUCIDITY Trial of Avexitide for Post-Bariatric Hypoglycemia Presenter: Marilyn Tan, MD Poster Number: MON-617 Session Title: Diabetes and Vascular Disease: Hypoglycemia III Date and Time: Monday, June 15, 2026, 12:00 p.m. – 1:30 p.m. CT About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). In PBH, an exaggerated GLP-1 response leads to excessive insulin secretion, resulting in recurrent hypoglycemic events. Avexitide is a GLP-1 receptor antagonist designed to competitively bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the exaggerated GLP-1-driven insulin response characteristic of PBH, reducing inappropriate insulin secretion and stabilizing blood glucose levels. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events...

View stock analysis, news, and events for Amylyx Pharmaceuticals, Inc.